Skip to main content

Development, characterisation and validation of new and original models for Alzheimer's Disease'

Objective

Alzheimer's disease (AD) is characterized by a progressive loss of cognition and memory function, and is defined pathologically by the deposition of amyloid peptide and neurofibrillary tangles and by a marked cortical cholinergic depletion. In the sporadic form of AD, multiple mechanisms can lead the formation of tangles and plaques. Aim: The MEMORIES hypothesis driven project gathers together 8 partners from 5 different countries towards the aim of developing, characterising and validating new animal models that have a real potential for becoming a gold standard in the AD field. Background/rationale: AD is a complex neurodegeneration possibly determined by multiple molecular mechanisms. One recent finding demonstrated that it can be linked to an unbalanced signaling and processing of the pro-NGF/NGF and pro-BDNF/BDNF signalling pathways. Moreover, the involvement of SorLA, a member of a novel family of vacuolar protein sorting 10 protein (Vps10p)-domain receptors, in APP processing and trafficking has been recently suggested. On the basis of these molecular mechanisms, new mouse models will be created. Description: towards the MEMORIES aim, a panel of mouse models will be, using a multidisciplinary approach, produced and analyzed for the presence of neurodegeneration. These mice will express specific antibodies neutralizing TrkA receptors or mutated form of pro-NGF. AD11 anti-NGF, which already represent a good model for sporadic AD, will be crossed to mice in which the human APP or Tau are over-expressed or to mice in which pro-convertases or the TrkB or SorLA receptors are knocked-out. Mice will be analyzed using standardized for neuroanatomy and behavioural analysis. Anticipated output: We anticipate that by blocking different signaling pathways will help in ameliorating the current available experimental mouse models, being also useful to develop new therapeutic tools for this disease and strengthen European competitiveness in the war against'.

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

"RITA LEVI-MONTALCINI" EUROPEAN BRAIN RESEARCH INSTITUTE FOUNDATION
Address
Via Del Fosso Di Fiorano, 64
Rome
Italy

Participants (10)

NEURÉVA INC.
France
Address
3, Rue Trésoriers De La Bourse
Montepellier
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
Germany
Address
Robert-roessle-str., 10
740238 Berlin
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Germany
Address
Meyerhofstrasse 1
Heidelberg
HELSINGIN YLIOPISTO
Finland
Address
Yliopistonkatu 4
Helsingin Yliopisto, Helsinki
SWISS INSTITUTE FOR EXPERIMENTAL CANCER RESEARCH
Switzerland
Address
Chemin Des Boveresses 155
Epalinges
ACIES
France
Address
69 Rue De La République
Lyon
NEURONICON APS
Denmark
Address
C/o Oestjutland Innovation A/s, Gustav Wieds Vej 10
Aarhus C
LAY LINE GENOMICS S.P:A
Italy
Address
Via Di Castel Romano 100
Rome
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE
Switzerland
Address
Bâtiment Ce - 3.316, Station 1
Lausanne
PROJETS ET RESEAUX DE RECHERCHE
France
Address
69 Rue De La République
Lyon